• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compositions comprising cartilage extracts, grape seed extracts and tomato extracts have been found to have significant antioxidant and free radical inhibition effects. Compositions of the present invention comprising hydrophilic antioxidants, lipophilic (hydrophobic) antioxidants and cartilage extracts dramatically increase collagen synthesis in the dermis. In addition, the composition of the present invention lowers the collagenase activity and the level of higher glycosylated end products (AGE). Signs of aging, such as photoaging due to UV radiation exposure, are related to the levels of collagen synthesis and free radical oxidation. The compositions of the present invention are for treating aging skin and for delaying onset of signs of aging in healthy skin.
    公开号:KR20030016259A
    申请号:KR1020027015160
    申请日:2001-05-10
    公开日:2003-02-26
    发明作者:벵트 크리스터 올손
    申请人:벵트 크리스터 올손；
    IPC主号:
    专利说明:

    Marine and plant extract combination composition {COMBINED MARINE AND PLANT EXTRACT COMPOSITION}
    [2] Free radicals are formed in the body, such as the skin, as a result of UV radiation, pollution, alcohol, and the like. Excess free radicals can cause serious damage to tissue structures, including skin structures, so signs of aging begin to appear.
    [3] Therefore, antioxidants are used that combine both hydrophilicity and lipophilic to reduce oxidative stress caused by free radicals in the skin ["Free Radical Scavenging and Anti-enzyme Activities of Procyanidines from Vitis vinifera" Arzneim.-Forsch. / Drug Res., 44 (1), Nr. 5 (1994), pp 592-601.
    [4] U.S. Patent 5,648,277 discloses oral formulations comprising hydrophilic antioxidants and lipophilic antioxidants.
    [5] JP 09 241637 discloses a composition comprising an active free radical scavenger and uronic acid or mucopolysaccharide.
    [6] It has also been demonstrated that the administration of protein complexes containing mucopolysaccharides derived from marine cartilage sources has the ability to improve the dermal tissue of the skin by making it more dense and harder [Kieffer ME, Efsen J., J. Eur. Acad. Dermatol. Venereol., 1998 Sep; 11 (2): 129-136.
    [1] The present invention relates to an oral composition, wherein the composition contains cartilage or compounds extracted from cartilage, as well as hydrophilic and lipophilic antioxidants.
    [7] Summary of the Invention
    [8] The inventors have found that the unique combination of cartilage extract with a special mixture of plant extracts results in a surprisingly effective composition that not only increases the synthesis of collagen in the skin but also significantly reduces radical mediated oxidation in the dermis. Both collagen synthesis and reduced radical oxidation are associated with the aging process of the skin.
    [9] In a first aspect, the present invention relates to a composition for oral administration comprising a plant extract and a cartilage extract, wherein the plant extract comprises a grape seed extract and a tomato extract.
    [10] Alternatively, the present invention may be defined as a composition for oral administration comprising a plant extract and a cartilage extract, wherein the plant extract comprises grape seed extract and lycopene of about 5: 1 to 15: 1, preferably about 10: 1. It includes by weight / weight ratio.
    [11] Another aspect of the invention relates to a composition for oral administration, the composition comprising: i) cartilage, one or more compounds extractable therefrom or derivatives thereof; ii) at least one hydrophilic antioxidant; And iii) at least one lipophilic antioxidant, wherein the composition increases at least 35% collagen synthesis in a cell model.
    [12] A composition as defined herein for the general maintenance of healthy skin and for the treatment of signs of skin aging, to delay the onset of skin degeneration due to aging or UV exposure, is another aspect of the present invention.
    [13] Detailed description of the invention
    [14] In general, in the context of the present invention, the term “hydrophilic” as applied to a hydrophilic antioxidant means that the antioxidant is sufficiently soluble in the aqueous medium in the body and thus can function in the aqueous medium in the body. In this specification, antioxidants are considered hydrophilic if they have a solubility in water of at least 0.05 g per 100 g of water. Preferably, the hydrophilic antioxidant is at least 0.5 g per 100 g of water, more preferably at least 1 g, particularly preferably at least 5 g, more particularly at least 10 g, most particularly preferably at least 25 g, even more, at least 50 g , For example, solubility in water of at least 100 g.
    [15] Similarly, the term “lipophilic”, which generally applies to lipophilic antioxidants, is sufficiently soluble in the lipid medium in the body, and thus can function in the lipid medium in the body. In this specification, antioxidants are considered lipophilic if they have a solubility in water of 0.05 g or less per 100 g of water. The lipophilic antioxidant preferably has a solubility in water of up to 0.005 g, in particular up to 0.0005 g per 100 g of water.
    [16] The term "cartilage extract" is intended to include cartilage, components that can be extracted from it, and derivatives thereof, including synthetic forms and synthetically prepared derivatives of compounds extractable from cartilage. Compounds called "cartilage extracts" can also be found in and extracted from other tissues containing joint tissues, such as skin or leather. Cartilage can be selected from the group consisting of marine animal cartilage, fish cartilage, mollusk cartilage and terrestrial mammalian cartilage. Marine animals may be selected from the group consisting of whales, dolphins and seals, fish may be selected from the group consisting of sharks, salmon, tuna, cod and other known fish, mollusks may be squids, terrestrial mammals It may be selected from the group consisting of cattle, pigs, chickens, ducks and turkeys. Cartilage or extract therefrom is preferably selected from bovine cartilage, pork cartilage, shark cartilage, squid cartilage, chicken cartilage and salmon cartilage, and extracts from them.
    [17] Cartilage itself can also be used. Typically, it can be used in the form of dry, for example lyophilized and ground cartilage. Typically, useful extracts of cartilage of the type described above or other tissues containing appropriate ingredients are prepared via partial enzymatic proteolytic hydrolysis of cooked tissue, followed by filtration drying, such as spray drying or freeze drying. can do. Such extracts have the advantage of being able to be partially or completely dissolved in an aqueous medium (prepared according to US Pat. No. 3,862,003).
    [18] Typically, the cartilage extract comprises one or more compounds extractable from cartilage and preferably comprises glycosaminoglycans, optionally bound to peptides. The cartilage extract preferably comprises chondroitin sulfate, keratan sulfate, hyaluronic acid or dermatan sulfate or mixtures thereof. The term "cartilage extract" is intended to include compounds obtainable from cartilage, but in practice the compounds may be obtained from other sources. A particularly preferred source of cartilage extract is shark cartilage.
    [19] The term “cartilage extract” may relate to a compound or derivative thereof extractable from cartilage. As mentioned above, cartilage extracts can be obtained from natural sources, but can also be obtained from synthetic sources, ie, synthetically or semisynthetically prepared. Cartilage extract is preferably extracted from a natural source, the extract is most preferably extractable from cartilage, the extract is particularly preferably extracted from cartilage.
    [20] As described above, in the first aspect, the present invention relates to a composition for oral administration comprising a plant extract and a cartilage extract, wherein the plant extract is about 2: 1 to 1: 2, preferably a grape seed extract and a tomato extract. Comprises in a weight / weight ratio of about 1: 1. The inventors have found that the unique combination of cartilage extract with a special mixture of plant extracts results in a surprisingly effective composition that not only increases the synthesis of collagen in the skin but also significantly reduces radical mediated oxidation in the dermis.
    [21] The beneficial effect of the combination of grape seed extract and tomato extract as an antioxidant was unexpectedly dramatically improved by adding cartilage extract. The result is surprising, in part because the cartilage extract does not have its own antioxidant activity.
    [22] Typically, the cartilage extract and the plant extract are present in a weight / weight ratio of about 1: 2 to 2: 1, preferably about 1: 1.
    [23] The cartilage extract preferably comprises glycosaminoglycans selected from the group consisting of chondroitin esters, keratan esters, hyaluronic acid or esters thereof, heparin, heparin esters. They are bound to proteins or peptides or are chondroitin esters, keratan esters, hyaluronic acid or esters thereof, dermatan esters, heparin, peparan esters, preferably chondroitin sulfates, keratan sulfates, hyaluronic acid or esters thereof It may be in the form of epimers or polymers of dermatan sulfate, heparin, heparan sulfate.
    [24] Glycosaminoglycans can be selected from the group consisting of chondroitin-4-sulfate, chondroitin-6-sulfate, and keratan sulfate, each optionally bound to a peptide. More preferably, the compositions of the present invention comprise cartilage extracts comprising chondroitin sulfate optionally bound to peptides.
    [25] In a typical embodiment of the present invention, the cartilage extract comprises 5-100% w / w chondroitin sulfate.
    [26] In a preferred embodiment, the composition of the invention comprises less than 1% w / w collagen, preferably less than 0.5% w / w, particularly preferably less than 0.1% w / w collagen protein. In the usual way of making collagen, it does not contain collagen in any suitable amount. The extract is preferably prepared by enzymatic proteolytic hydrolysis, thus breaking down collagen protein into peptides. Compositions containing these extracts with such low collagen levels have unexpectedly beneficial effects. As a result, it is preferred that no collagen or source thereof be added to the composition of the present invention. In the most preferred embodiment, the composition is essentially free of collagen.
    [27] Similarly, compositions of the present invention typically comprise less than 0.025% beta-carotene, preferably less than 0.02% beta-carotene, in particular less than 0.01% beta-carotene. Accordingly, another aspect of the present invention relates to a composition capable of achieving the beneficial effects as described below, with little or essentially no beta-carotene.
    [28] In contrast, it is currently recognized that the relative or absolute content of lycopene is particularly important for the unexpected beneficial effects of the compositions of the present invention. Plant extracts, especially tomato extracts, include lycopene. The tomato extract preferably comprises about 5-12% w / w, typically approximately 10% w / w lycopene. The tomato extract may be in the form of a single tomato or a mixture.
    [29] In a typical embodiment, the tomato variety used to prepare the tomato extract is Lycopersicum aesculentum , thereby providing appropriate absolute and relative levels of lycopene.
    [30] In a preferred embodiment of the invention, the composition comprises 0.1 to 5% w / w of lycopene, preferably 0.2 to 4% w / w lycopene, such as 0.3 to 2% w / w lycopene, most preferably 0.3 to 1 % w / w lycopene, in particular 0.3-0.8% w / w lycopene, such as 0.3-0.6% w / w lycopene.
    [31] In an alternative definition of the composition of the present invention, the composition comprises a plant extract and a cartilage extract, wherein the plant extract comprises about 5: 1 to 15: 1, preferably about 10: 1, grape seed extract and lycopene. Included in / weight ratio. As noted above, according to the present knowledge of the present invention, the ratio of lycopene is of significant importance in achieving a surprisingly beneficial antioxidant effect.
    [32] In a suitable embodiment, the antioxidant activity IC 50 of the lipophilic antioxidant is less than 1.2 × 10 −7 for scavenging R · ROO · in lipid peroxidation of unsaturated phospholipids in an aqueous medium. Typically, lipophilic antioxidants that exhibit an antioxidant activity IC 50 of 1.2 x 10 −7 or less in scavenging R · ROO · in lipid peroxidation of unsaturated phospholipids in aqueous media are also known as carotenoid conjugate lycopene (also, ψ, ψ-carotene). Typically, lycopene can be obtained by extracting from certain fresh fruits, such as tomatoes, watermelon, red grapefruit or guava fruit, in a manner known per se, or synthesized in a known manner.
    [33] The beneficial effect of the oral compositions of the invention is the result of a novel combination of three components: cartilage extract, grape seed extract and tomato extract. Tomato extract provides lipophilic antioxidants. Accordingly, the present invention relates to novel combinations of antioxidants and compounds extractable from cartilage. Accordingly, another aspect of the present invention relates to a composition for oral administration, the composition comprising: i) cartilage, one or more compounds extractable therefrom or derivatives thereof; ii) at least one hydrophilic antioxidant; And iii) at least one lipophilic antioxidant, wherein the composition increases at least 35% collagen synthesis in a cell model.
    [34] Collagen synthesis is markedly reduced in aged skin cells. Reduction of collagen in the skin leads to changes in the tissues and rheological aspects of the skin and to the usual signs of aging such as wrinkles, reduced smoothness, loss of elasticity and stiffness.
    [35] As shown in FIG. 2, the compositions of the present invention dramatically increased collagen synthesis as compared to other formulations and individual components. The synthesis of collagen was assessed by measuring the amount of radioactive proline ([ 14 C] -proline) introduced into the proline-containing protein, the majority of which is 30% of the total number of amino acids being proline.
    [36] Dermal fibroblasts cultured in a medium containing a combination of grape seed (G) extract and tomato (T) extract (as disclosed in US Pat. No. 5,648,277) had a reduced degree of proline introduction compared to the control group. That is, the 3.6% introduction is 25% reduced compared to the control of 4.8% introduction. Cell cultures containing a combination of fish (F) and tomato (T) extracts (FT) did not show a significant effect on proline introduction because the introduction rate was 5.0% compared to the control at 4.8% introduction. As an introduction, it is only a 4% increase. Cell cultures containing a combination of fish (F) and grape seed (G) extracts (FG) had a slightly increased proline introduction rate, a 10% increase with a 5.5% introduction compared to the control. Cell cultures containing only fish (F) extracts had an increased rate of proline introduction, ie a 29% increase with 6.2% introduction.
    [37] However, cells cultured with the composition (FGT) according to the invention comprising fish extract (F), grape seed extract (G) and tomato extract (T) had a dramatic 80% increase in proline introduction rate (introduced 8.4% proline). ). While GT extracts reduced collagen synthesis by 25% and F extracts increased collagen synthesis by 29%, it was surprising that 80% of collagen synthesis increased when F and GT were combined.
    [38] The at least one hydrophilic antioxidant of the composition of the present invention may be in the form of a natural or synthetic source, preferably a natural source. In a typical embodiment, the natural source is pine bark, Vitis vinifera , Camelia sinensis , Aesculus hippocastanum , Gingo biloba , Carr Cardus marianum , Vaccinium myrtillus and Silybum marianum .
    [39] In a suitable embodiment, the one or more hydrophilic antioxidants can be extracted from the grape seeds of Vitis vinifera.
    [40] Typically, the natural source of one or more hydrophilic antioxidants is 25% w / w or less of catechins, epicatechins and gallic acid; 90% w / w or less of epicatechin dimers, trimers and / or tetramers, and / or gallates thereof; And up to 10% w / w of epicatechin pentameric, hexameric and / or heptamers, and / or gallates thereof.
    [41] One or more hydrophilic antioxidants include polyphenols and esters thereof; Ascorbic acid (vitamin C) and esters thereof; And it can be selected from the group consisting of pharmaceutically acceptable salts thereof. Typically, polyphenols are catechins; Leucoanthocyanidins and flavanones; Flavanine, flavones and anthocyanins; Flavonols; Flavonoligands; And oligomers thereof.
    [42] In a preferred embodiment, the hydrophilic antioxidant is catechin selected from the group consisting of proanthocyanine A2 and oligomer procyanidol (OPC), most preferably oligomer procyanidol.
    [43] Typically, the flavonoligand is silymarin or one of its components, such as silybin, sillydinin, sillycristine and isosilbin.
    [44] In the compositions of the present invention, hydrophilic antioxidants typically exhibit an antioxidant activity IC 50 of 5 x 10 -7 or less in scavenging R./ROO .. in lipid peroxidation of unsaturated phospholipids in an aqueous medium.
    [45] As noted above, preferred hydrophilic antioxidants are extracts from grape seeds, i.e., seeds of Vitis vinifera, which typically extracts grape seeds using organic solvents such as acetone and / or ethyl acetate and extracts the solvent. It is evaporated and the residue is redissolved in water and the filtrate is obtained by filtration drying, for example by spray drying or freeze drying. In particularly preferred embodiments, typically such extracts comprise up to 25% w / w of catechins, epicatechins and gallic acid; 90% w / w or less of epicatechin dimers, trimers and / or tetramers, and / or gallates thereof; And up to 10% w / w of epicatechin pentameric, hexameric and / or heptamers, and / or gallates thereof.
    [46] The one or more lipophilic antioxidants can also be obtained from natural or synthetic sources, usually from natural sources. The lipophilic antioxidant can be a mixture of antioxidants, such as extracts from natural sources, including complex mixtures of lipophilic antioxidants. A suitable natural source of lipophilic antioxidants is the tomato variety, in particular the lycoppericum asculentum variety.
    [47] Typically, the one or more lipophilic antioxidants are carotenoids, procarotenoids, tocopherols, phytosterols and ubiquinones. Carotenoids are of particular interest to lipophilic antioxidants and include α-carotene, β-carotene, γ-carotene, δ-carotene, lycopene (ψ, ψ-carotene), zeaxanthin, cryptoxanthine, lutein and xanthophyllo. It may be selected from the group consisting of.
    [48] As mentioned above, carotenoid lycopene is a lipophilic antioxidant of particular interest. Most preferably, the composition of the present invention contains lycopene. The extract serving as a source of lipophilic antioxidants preferably contains 5 to 12% lycopene, such as 7 to 12% lycopene, preferably approximately 10% lycopene. Typically this is 0.1 to 5% w / w lycopene, preferably 0.2 to 4% w / w lycopene, such as 0.3 to 2% w / w lycopene, most preferably 0.3 to 1% w / w lycopene, in particular 0.3 To 0.8% w / w lycopene, such as 0.3 to 0.6% w / w lycopene.
    [49] Preferably, the natural source of lipophilic antioxidants is:
    [50] Lycopene 5-12%
    [51] Tocopherol 1-1.5%
    [52] Beta-carotene 0.05 to 0.15%
    [53] Phytophene 0.5 to 0.75%
    [54] Phytofluene 0.5 to 0.55%
    [55] It includes.
    [56] Most preferably:
    [57] Lycopene 7-12%
    [58] Tocopherol 1-1.5%
    [59] Beta-carotene 0.05 to 0.15%
    [60] Phytophene 0.5 to 0.75%
    [61] Phytofluene 0.5 to 0.55%
    [62] It includes.
    [63] Preferably, the source of at least one lipophilic antioxidant is less than 1% beta-carotene, such as less than 0.75%, such as less than 0.5%, preferably less than 0.25%, most preferably less than 0.2%, especially 0.15% Less than beta-carotene. Similarly, compositions of the invention typically comprise less than 0.025% beta-carotene, preferably less than 0.02% beta-carotene, in particular less than 0.01% beta-carotene.
    [64] Accordingly, another aspect of the invention relates to a composition capable of achieving the beneficial effect as described below, with little or essentially no beta-carotene.
    [65] In a typical embodiment, the sole source of lipophilic antioxidant is provided as a tomato extract. Alternatively, the lipophilic antioxidant is a tomato extract.
    [66] In a typical embodiment of the invention, the composition is
    [67] 20 to 40% w / w cartilage extract, such as 25 to 35% w / w, preferably 27 to 35% w / w, such as 30 to 35% w / w cartilage extract;
    [68] 1 to 10% w / w grape seed extract, such as 2 to 8% w / w, preferably 3 to 7% w / w, such as 3 to 5% w / w grape seed extract; And
    [69] 1 to 10% w / w tomato extract, such as 2 to 8% w / w, preferably 3 to 7% w / w, such as 3 to 5% w / w tomato extract
    [70] It includes.
    [71] Typical compositions of the present invention comprise fish extract (F), grape seed extract (G) and tomato extract (T) in a weight ratio of about 5: 1: 1 to 15: 1: 1, such as about 10: 1: 1. .
    [72] As noted above, the compositions of the present invention can increase collagen synthesis by at least 35% as measured by Test Method A. However, preferably using the composition under the conditions of Test Method A, collagen synthesis is at least 40%, such as at least 45%, such as at least 50%, at least 55%, preferably at least 60%, such as at least 65%, Increase by at least 70%, most preferably at least 75%.
    [73] Accordingly, another aspect of the present invention relates to a method of increasing collagen synthesis or decreasing collagen synthesis reduction, comprising oral administration of a composition as defined herein.
    [74] We have found that the novel compositions of the invention not only increase collagen synthesis, but also have other indicators of their use for the treatment of skin exposed to aging or UV radiation. Thus, in a suitable embodiment, the composition exhibits a deleterious effect of free radicals of at least 40%, such as at least 45%, such as measured by MMP-1 activity as compared to the control under the conditions of test method B. Reduce by more than 50%. Typically, oxygen free radicals and the deleterious effects therefrom are due to UV exposure but may also result from other environmental, physiological or genetic factors.
    [75] UV-induced overproduction of MMPs is thought to be one of the main causes of photoaging. UV radiation activates dermal cells, leading to overproduction of MMP, an enzyme that degrades collagen and other proteins, including the dermal extracellular matrix. After dermal disintegration (decay) there is an incomplete recovery. Incomplete repair impairs the structural integrity of the dermis, which is repeated with intermittent exposure to each UV radiation resulting in accumulation of dermal scars, eventually resulting in visible signs of photoaging (2-5). The effect of UV light on MMP induction was also confirmed in fibroblast cultures (6,7). Other studies that focus on the mechanism of UV-induced MMPs suggest that UV-induced singlet oxygen (reactive oxygen species) has a direct effect on cells, leading to the production of MMPs. Thus, antioxidants, and especially scavenging singlet oxygen, will neutralize UV stimulated MMP synthesis. However, it cannot also be excluded that other free radical species are involved in stimulation of MMP synthesis. Older cells in culture as well as UV or sun exposed skin cells produce higher amounts of MMPs. Thus, the reduction in MMP-1 activity as a result of using the compositions of the present invention is an indicator of its use for the maintenance of healthy skin.
    [76] Moreover, the compositions of the present invention have at least 10%, such as at least 20%, such as at least 20%, such as 30%, 40%, 50, formation of higher glycosylation end products (AGE) as measured under the conditions of test method C when compared to the control By at least% or 60%, preferably at least 70%, in particular at least 80% or 90%, most preferably at least 100% or 110%.
    [77] AGE (advanced glycosylation end product, also known as Amadori product) is the result of glycosylation (glycooxidation), a nonspecific reaction between protein and carbohydrates. AGE accumulates both in individual cells and in extracellular matrix containing proteins of long lifespan, such as collagen in skin. AGE crosslinked proteins are nonfunctional proteins, tend to aggregate in the extracellular matrix or the cytoplasm of the cells, and are believed to have deleterious effects on overall protein synthesis. Initially, when glucose reacts with the protein, an early stage product (probably the product) is formed. This amadori product then undergoes further relocation reactions to form later stage brown pigments that can crosslink the protein. After the rearrangement reaction, later stage products continue to accumulate in long-lived proteins such as collagen over a long period of time with high crosslinking of the protein. In vivo AGE formation has been shown to increase with organic and cellular aging both in vivo and in vitro. In vivo, the levels of AGE accumulation are thought to reflect serum glucose levels. An important role in the formation of later stages of AGEs is described as oxidation, because glycosylation itself is a reversible process. However, oxidation causes permanent chemical damage and loss of protein function due to permanent crosslinking (9). Apart from being inefficient and having a diminishing effect on overall protein synthesis, AGE has been shown to be a chromophore that generates significant amounts of free radicals after being irradiated with UV light (10). Thus, oxidative stress contributes to AGE formation.
    [78] For a single dose of exposure to UV radiation (5 J / cm 2), the AGE level of unsupplemented control cells increased approximately 20-fold compared to unirradiated control cells. Under the same conditions, AGE levels in cultures supplemented with F increased approximately 40-fold, indicating that F had no protective effect on AGE formation upon UV irradiation. The increase in AGE levels of F treated cells is more dramatic at 7.5 J / cm 2. From FIG. 3, the AGE level of cells supplemented with FG was found to be increased by 72 units, which is the same range as untreated irradiated control cells (10% reduction compared to control).
    [79] Remarkably, FGT cell treated cells showed a surprising decrease in AGE levels of approximately 22 units compared to unirradiated cells, which translates to a 120% decrease in AGE concentrations compared to untreated irradiated cells.
    [80] The compositions of the present invention not only have improved proline introduction, but also provide a beneficial effect on UV exposed cells with respect to MMP-1 activity and AGE formation.
    [81] Accordingly, another aspect of the present invention relates to compositions suitable for cosmetic treatment of signs of skin aging and general maintenance of healthy skin. Signs of aging can be the result of a number of factors such as daylight, time of day, diet and other environmental conditions.
    [82] Typically, the composition of the present invention
    [83] Compound 1-80% w / w extractable from cartilage;
    [84] Grape seed extract 0.1-75% w / w; And
    [85] Lycopene 0.002 to 25% w / w
    [86] It includes.
    [87] The composition of the present invention
    [88] Cartilage extract 27-35% w / w, typically 30-35% w / w;
    [89] Grape seed extract 1 to 10% w / w, such as grape seed extract 3 to 5% w / w; And
    [90] Lycopene 0.1-5% w / w, typically 0.2-1% w / w
    [91] It is most preferable to include.
    [92] The present inventors
    [93] Fish extract 100-110 mg;
    [94] Plant extracts 95-105 mg;
    [95] Acerola extract 25-35 mg;
    [96] 60 to 90 mg of microcrystalline cellulose; And
    [97] Silicon dioxide 3.5 to 4.5 mg
    [98] A suitable composition was prepared, wherein the plant extract comprises oligomer procyanidol and lycopene, and the fish extract comprises glycosaminoglycans.
    [99] Suitable compositions according to the present invention
    [100] Fish extract 100-110 mg;
    [101] Plant extracts 95-105 mg;
    [102] Inulin 60-65 mg;
    [103] Ascorbic acid 25 to 35.00 mg;
    [104] Zinc gluconate 10-20 mg; And
    [105] 10 to 15 mg of silicon dioxide
    [106] Wherein the plant extract comprises oligomeric procyanidol and lycopene, and the fish extract comprises glycosaminoglycans.
    [107] Thus, the compositions of the present invention may further comprise other ingredients, such as additional nutritional additives such as vitamins, minerals, amino acids and carbohydrates. In a preferred embodiment, the composition may further comprise an extract comprising vitamin C or vitamin C, such as acerola extract.
    [108] As mentioned above, according to the present understanding of the present invention, the relative and absolute amounts of the constituents are important in order to obtain the surprising benefits of the compositions of the present invention. Thus, hydrophilic and lipophilic antioxidants are preferably present in a weight / weight ratio of about 1: 1 to about 200: 1, such as 2: 1 to 100: 1, especially 5: 1 to 50: 1, especially 5: 1 to 20: 1, preferably 5: 1 to 15: 1, most preferably about 7: 1 to 12: 1, such as about 10: 1.
    [109] Similarly, cartilage, at least one compound extractable therefrom, and hydrophilic antioxidant are preferably present in a weight / weight ratio in the range of about 1: 1 to about 200: 1, such as 2: 1 to 100: 1, in particular 5: 1 to 50: 1, particularly 5: 1 to 20: 1, preferably 5: 1 to 15: 1, most preferably about 7: 1 to 12: 1, such as about 10: 1 do.
    [110] In general, an important aspect of the invention is that i) cartilage, at least one compound or derivative thereof extractable therefrom, ii) at least one hydrophilic antioxidant, and iii) at least one lipophilic antioxidant are cultured in vitro. The present invention relates to a composition present together in an amount sufficient to inhibit MMP-1 activity, inhibit AGE formation, or increase collagen formation in human fibroblasts.
    [111] Similarly, another important aspect of the invention is that i) cartilage, one or more compounds extractable therefrom, or derivatives thereof, ii) one or more hydrophilic antioxidants, and iii) one or more lipophilic antioxidants in vitro It relates to a composition present in a proportion sufficient to inhibit MMP-1 activity, inhibit AGE formation, or increase collagen formation in cultured human fibroblasts.
    [112] In a combination of preferred embodiments, the composition comprises 0.25 to 15 mg of lycopene and 5 to 20 mg of grape seed extract, specifically 0.75 to 2.5 mg of lycopene and 10 to 30 mg of grape seed extract, in particular 1 to 2.5 mg of lycopene and 10 to 25 mg of grape seed extract. It may include.
    [113] In a further combination of embodiments, the composition may comprise 1 to 2.5 mg of lycopene, 5 to 50 mg of grape seed extract and 50 to 200 mg of cartilage extract.
    [114] The compositions of the present invention are for oral administration and may be administered in the form of solid formulations such as tablets, powders, granules, capsules, sachets or liquid formulations such as solutions, suspensions, isotonic syrups. Such formulations may be prepared by methods well known in the art of pharmacy, and may contain one or more excipients which may be any conventionally used in the art. In solid compositions, conventional nontoxic solid excipients include pharmaceutical grade mannitol, lactose, starch, soy fiber, magnesium stearate, sodium saccharin, talc, cellulose such as microcrystalline cellulose, glucose, saccharose, silicon dioxide, magnesium carbonate Etc., but is not limited thereto. Liquid formulations can be obtained by dissolving or dispersing the active ingredient and any pharmaceutical adjuvants in an excipient such as water or an aqueous liquid such as juice, oil or alcohol to form a solution or suspension. If desired, oral compositions according to the invention may also comprise small amounts of additives known in the art, such as wetting or emulsifying agents, buffers and the like. Such formulations are well known in the art, such as in Remington's Pharmaceutical Sciences , Mack Publishing Company, Easton, Pennsylvania, 15th edition, 1975; Or Martindale, The Extra Pharmacopeia , The Royal Pharmaceutical Society of Great Beitain, 31st edition, 1996.
    [115] The composition may allow a lipophilic antioxidant, such as a tomato extract, or an extract comprising lycopene, to be formulated for normal release, and the lipophilic antioxidant, such as a grape seed extract, may be formulated for delayed release or sustained release. have.
    [116] As illustrated in Example 5, the composition, when administered orally, has a clear visible effect on the condition of the skin. In addition, Figure 4 presents data that can identify significant improvements in the prerequisite skin condition, flexibility, quality of the skin around the eye and quality of the skin around the mouth in volunteers receiving the composition of the present invention. Thus, the results of Examples 1-4 have been successfully interpreted in vivo, and the compositions are believed to act systemically when administered orally on the surface.
    [117] The compositions of the present invention can be used as oral cosmetics, food or food additives, drugs or dietary foods.
    [118] Another aspect of the invention relates to compositions for use in general maintenance of healthy skin and compositions for treating signs of aging in the skin that delay the onset of skin degeneration due to aging or UV exposure. The compositions of the present invention are for aging skin, skin exposed to sunlight or other forms of ultraviolet radiation, dry skin, rough skin, discolored skin, eczema skin, scarred skin, stretch marks, acne or psoriasis. It is suitable for treating skin with teeth.
    [119] Signs of skin aging, and methods of cosmetic or prophylactic treatment of skin for damage due to UV radiation exposure include oral administration of the compositions described above, which is an important aspect of the present invention. Similarly, cosmetic treatment of aging skin, skin exposed to sunlight or other forms of ultraviolet radiation, dry skin, rough skin, bleached skin, eczema skin, scarred skin, stretch marks, acne or psoriasis skin Or prophylactic treatment methods include oral administration of the above-described composition, which is another important aspect of the present invention. Preparations for preventing or reducing the signs of skin aging, preparations for preventing or reducing the deleterious effects of ultraviolet exposure, preparations for treating stretch marks, preparations for treating eczema, reducing the signs of acne using the compositions of the present invention as described above. Formulations, formulations that assist in scar formation and wound healing, formulations that reduce scars, formulations that reduce the manifestation of psoriasis, or formulations that treat rough, discolored or dry skin can be prepared.
    [120] In these applications, a typical daily usage based on the average adult is 55 to 3600 mg, such as 70 to 1000 mg, of the mixture of cartilage components, hydrophilic antioxidants and lipophilic antioxidants described above. The administration may be administered once daily, divided into several times a day, for example divided into 1, 2, 3 or 4 times daily, preferably 1 or 2 times daily.
    [121] The composition may be packaged according to general principles well known in the art such as tablet containers, blister packs or bottles. If one of the components is sensitive to light, particularly if the lipophilic antioxidant is lycopene, the packaging material is preferably capable of blocking light. For example, in the case of blister packs, the blister packs are each thin with plastic / aluminum laminates (eg, laminates of PVC, aluminum, and oriented polyamide foils), and shaped as needed, polished aluminum foil (with depressions formed). In the case of a well-known form using two aluminum foils and an aluminum coated plastic foil, such as a sheet), appropriately obtained.
    [122] The invention will be further described by the following non-limiting examples.
    [123] Example 1
    [124] Determination of Effective Concentrations of Hydrophilic Antioxidants, Hydrophobic Antioxidants, and Cartilage Extracts
    [125] Dose-dependent doses of grape seed extract (1 to 200 μg / ml), cartilage extract (0 to 1000 mg / ml) and tomato extract (0 to 200 μg / ml) in human skin fibroblasts cultured in vitro Was tested in a manner. After evaluating cell viability and growth rate under all culture conditions, the DAIL optimal concentration for each component was selected.
    [126] Way
    [127] A mother liquor consisting of cartilage extract, grape seed extract and lycopene containing tomato paste was prepared as follows:
    [128] Cartilage solution (40 mg / ml):
    [129] 200 mg of fish powder (cartilage extract prepared by proteolytic hydrolysis using enzymes of cartilage, filtration of hydrolysates and spray drying) was dissolved in 5 ml of Hank buffered saline solution (hank) and sterile filtered.
    [130] Grape Seed Solution (40 mg / ml):
    [131] 200 mg of grape seed extract (Milan Indena, Italy) was dissolved in 5 ml of Hank's buffered saline solution (Hank) and sterile filtered.
    [132] Tomato solution (prestock solution: 100 mg / ml)
    [133] Prostock solution: 400 mg of tomato paste (containing 40 mg of lycopene) was dissolved in 4 ml of tetrahydrofuran, sterile filtered and stored at -80 ° C until use.
    [134] Tomato mother liquor (100 μg / ml):
    [135] Tomato mother liquor: Immediately before use, the prestock solution was diluted 1: 1000 in cell medium DMEM.
    [136] Human fibroblasts were cultured as follows:
    [137] 10,000 cells / well were seeded in a 24-well tray. After allowing the cells to attach overnight, the medium was exchanged with medium containing cartilage extract (F), grape seed extract (G) and tomato extract (T) at different concentrations. The cell medium, DMEM (10% calf serum albumin, + glutamine, penicillin / streptomycin) was exchanged every two or three days, except for the medium containing TE regenerated daily. Cells were grown until fusion (37 ° C., 5% CO 2 , 95% humidity), using 200 μl to count the number of cells per ml for 10 minutes in an incubator at 37 ° C. Cells were counted every 2 days using 300 μl trypsin / EDTA pr. Wells to isolate.
    [138] Cell survival and cell growth were assessed after up to 15 days.
    [139] Cell survival was assessed by measuring intracellular MTT uptake. Uptake levels corresponded to mitochondrial activity levels that can be used as an indicator of cell viability. MTT was reduced to formazan, a blue colored compound, which was detected by UV / VIS absorption at 595 nm using 655 nm as reference.
    [140] Cell growth was assessed as the number of cells per culture flask counted using an electronic counter cooler®.
    [141] result
    [142] Cell cultures supplemented with cartilage extract 70 μg / ml, grape seed extract 10 μg / ml and tomato extract 10 μg / ml (= 1.0 μg / ml of lycopene) provided an optimal environment for cell growth. These concentrations were not toxic and did not change the rate of cell division. These results were further confirmed by prolonged culturing of fibroblasts over 50 days in culture medium supplemented with the selected formulations (above). The monitored cumulative population doubling level (CPDL) corresponding to cell division and cell growth was not affected by the tested components. The results are shown in Table 1 below and FIG. 1.
    [143] WorkOFFGTGT 018181818 319.1719.3418.8718.8 921.421.5221.2821.32 1423.0822.9323.0523.02 2125.6525.8725.5925.67 2827.5327.5727.7327.78 3528.8828.8829.229.15 4231.4531.5431.432.03 5032.9833.1433.4233.39
    [144] Example 2
    [145] Effect of the composition on collagen synthesis
    [146] In vitro test systems were used to test the effects of F, G, and T on collagen synthesis. Collagen synthesis was assessed by measuring radioactive proline ([ 14 C] -proline) incorporated into a proline-containing protein that is considered almost collagen, with the number of proline residues making up at least 30% of the total amino acid number. Various combinations of the optimal concentrations of F, G, and T measured as described in Example 1 were added to the cell medium and the radioactivity of the secreted and labeled proteins was measured after 24 hours.
    [147] Way
    [148] Extracts of F, G and T were prepared in the same manner as in Example 1.
    [149] The incorporation of radiolabeled proline in human fibroblast cell culture was performed as follows (test method A): Various combinations of F, G and T were added on the day of seeding and the cells were allowed to fuse (about 1). Week) to grow. Culture medium was changed daily. Upon fusion, the medium was exchanged with 2.5 mL of radioactive solution (25 μCi) plus 2.5 mL of medium containing no F, G or T.
    [150] Cells were left in the incubator for 24 hours, then the medium was collected and radiometric procedures were performed:
    [151] TCA precipitation: 5 μl of medium was mixed with 20 μl of BSA (0.5 g / L) and 1 mL of TCA (10%) and left at −20 ° C. for 30 minutes. Samples were thawed and treated with nitrocellulose filters to separate free radioactive proline from labeled proteins. The filter was transferred to a tube and 2.5 ml of flash solution was added. The tube was left in the dark for 1 hour and the radioactivity of 5 μl of sample was measured on a scintillation counter.
    [152] result
    [153] The results of this experiment are shown in Tables 2a and 2b below. Cell cultures containing the GT extract reduced the degree of proline incorporation compared to the control: 3.6% incorporation compared to 4.8% incorporation in the control, indicating a 25% reduction. Cell cultures containing FT extracts did not have a significant effect on proline incorporation because the degree of incorporation was 5.0% compared to 4.8% of the control, which meant only a 4% increase. Cell cultures containing FG extracts slightly increased the degree of proline incorporation, which was 5.5%, indicating a 10% increase over the control.
    [154] Cell cultures containing F extract increased the degree of proline incorporation: the degree of incorporation was 6.2%, which means a 29% increase. However, the FGT extract showed surprising results, with 8.4% incorporation of proline resulting in an 80% increase in proline incorporation.
    [155] In this type of experiment, a difference of at least 30% is considered significant.
    [156] processActive (dpm)Activity (μCi product)Proline incorporation rate (%)Results for the control GT45160.00153.620% increase Control57580.00204.8- FT45160.00215.0No change FG51370.00235.510% increase F57870.00266.230% increase FGT77380.00358.480% increase
    [157] Example 3
    [158] Effect of the composition on human fibroblasts upon UV exposure
    [159] UVA exposure is the cause of a number of denaturation changes in the skin that cause visual signs of aging (photoaging). Potential protective effects of F, G and T extracts and combinations thereof against UV induced damage were tested by monitoring biological markers associated with photoaging (levels of MMP-1 and AGE) in dermal fibroblast cultures upon UV irradiation.
    [160] Human fibroblast cell cultures were exposed to 1 dose of UVA irradiation daily for four consecutive days. Two different doses (5 and 7.5 J / cm 2) were used, corresponding to the maximum dose the cells tolerate before cell death occurred.
    [161] Cell cultures are supplemented with various F, G and T combinations (F, FG, FT, GT and FGT) using optimal concentrations of F, G and T (as described and determined in Example 1). MMP-1 activity and AGE formation were measured after 1 day and after 4 days.
    [162] Way
    [163] Extract was prepared in the same manner as in Example 1.
    [164] Culture of the cells was performed as follows:
    [165] Following subculture, cells were cultured in medium containing F, G and T treated combinations. Upon fusion they were split 1: 4 to give four flasks for each treatment. During fusion, one (1: 4 split) or two (1: 2 split) performed a series of passages in four new flasks.
    [166] UVA irradiation of the cell culture was performed as follows:
    [167] UVA dose was generated using 6 × Philips 40W UVA Cleo Performance Tubes. The dose was measured in units of W / m 2 using a Hagner UVA meter, and the required doses of 5, 7.5, 10 and 15 J / cm 2 were obtained by calculating the time required for exposure. As a result of preliminary experiments, the optimum dose which does not cause cell death was 7.5 J / cm 2.
    [168] Determination of MMP-1 activity (implicit activity + latent activity) was performed using code RPN 2629 commercially available from APB Biotech (Test Method B).
    [169] Measurement of AGE was performed based on ELISA technique (test method C):
    [170] Day 1: Microplates were coated with ng 50 ng per well and diluted in carbonate buffer overnight at + 4 ° C.
    [171] Day 2: Wells were washed four times with PBST (PBS and 0.05% Tween 20) and then blocked with 200 μl of PBS-milk (6%) per well for 2 hours at room temperature (RT). The wells were then washed four times with PBST, then 50 μl of AGE standard (20-20,000 units / well) or 50 μl of sample (50 μg protein / ml) was added to the wells, and the AGE polyclonal antibody (1 50 μl) were added. The plate was placed on a high speed stirrer for 2 hours at room temperature. Wells were washed four times with PBST, then secondary antibody (polyclonal rabbit, HRP, 1/1000 dilution) was added 50 μl per well and placed on a stirrer for 2 hours at room temperature. Finally, the wells were washed four times with PBST, and then 100 μl of substrate (1 OPD purified / 3 ml ddH 2 O + 1/1000 (v / v) of hydrogen peroxide (35%)) was added to each well. . The plate was left in the dark, and after appropriate color development, the reaction was stopped by adding 50 µl of sulfuric acid (1 M). Plate absorbance was read at 490 nm (reference wavelength 655 nm).
    [172] result
    [173] Results for MMP-1 activity and AGE formation are shown in FIGS. 2 and 3, respectively.
    [174] I. MMP-1 Activity
    [175] UVA irradiation was found to induce MMP-1 activity in untreated cells (control) in both day 1 and day 4 studies, demonstrating MMP-1 induction in cultured fibroblasts by UVA. MMP-1 activity of control cells was about twice the value during photoaging.
    [176] Cells treated with GT showed 34% and 58% increase at 1 and 4 days, respectively.
    [177] In contrast, MMP-1 activity was induced in cells supplemented with F. MMP-1 activity was about 3 and 4 times after UV exposure at 1 and 4 days, respectively.
    [178] Surprisingly, FGT combinations combining F and GT did not show an increase in MMP-1 activity in UV exposed cells. Thus, FGT treated cells showed half the activity of MMP-1 activity of control cells under the same conditions.
    [179] 1 day0 J / ㎠5 J / ㎠7.5 J / ㎠ ControlOne2.011.80 GTOne1.341.34 FGTOne0.970.99
    [180] 4 days0 J / ㎠5 J / ㎠7.5 J / ㎠ ControlOne2.022.3 GTOne1.371.58 FGTOne1.040.99
    [181] II. AGE formation
    [182] The results are shown in Figure 3 and Table 4. Upon UV exposure at a single dose (5 J / cm 2), AGE levels in unsupplemented control cells increased about 20-fold compared to unirradiated control cells. Under the same conditions, AGE levels in cultures supplemented with F increased 40-fold, indicating that F had no protective effect on AGE formation upon UV exposure. As can be seen from FIG. 3, AGE levels in cells supplemented with FG increased 72 units, which was in the same range as untreated exposed control cells (10% increase over control).
    [183] FGT treated cells showed a remarkable decrease of about 22 units of AGE resin compared to unexposed cells, which translates to a 120% reduction in AGE concentrations compared to untreated exposed cells.
    [184] Thus, the compositions of the present invention provide a beneficial effect on UV exposed cells in terms of proline incorporation as well as MMP-1 activity and AGE formation.
    [185] 5 J / ㎠7.5 J / ㎠ Control80.0667.88 F152.72258.21 G72.04118.58 FGT-21.94-34.92
    [186] Example 4
    [187] The compositions of the present invention are prepared by mixing the components described below in the indicated ratios (the amounts presented are based on the final dosage unit).
    [188] Because lycopene is susceptible to oxidation, mixing and handling of granules, compression of tablets, storage of tablets and packaging in aluminum-aluminum-blister cards were all performed under protective nitrogen.
    [189] Composition 1 (Tablet Code SF)
    [190] 105 mg of cartilage extract (prepared by enzymatic proteolytic hydrolysis of cartilage, filtration of hydrolysates and spray drying);
    [191] 100 mg of plant extract (about 1.5 mg of lycopene extracted from tomato and about 14 mg of flavonoids extracted from grape seeds, the residue being soy fiber, tomato oil and silicon dioxide; Alextan® from Milan Indenda, Italy) ;
    [192] 30 mg of acerola extract (containing about 7.5 mg of ascorbic acid, the residue being the acerola component and maltodextrin);
    [193] 66 mg of microcrystalline cellulose; And
    [194] 4 mg of silicon dioxide (particle size between 2.4 and 3.6 μm).
    [195] Mixing was carried out for 6 minutes in a solidly mixer. The powder mixture was compressed into tablets weighing 305 mg.
    [196] Composition 2 (Tablet Code SF-1)
    [197] 105 mg of cartilage extract (prepared by enzymatic proteolytic hydrolysis of cartilage, filtration of hydrolysates and spray drying);
    [198] 100 mg of plant extract (about 1.5 mg of lycopene extracted from tomato and about 14 mg of flavonoids extracted from grape seeds, the residue being soy fiber, tomato oil and silicon dioxide; Alextan® from Milan Indenda, Italy) ;
    [199] 30 mg of acerola extract (containing about 7.5 mg of ascorbic acid, the residue being the acerola component and maltodextrin);
    [200] 81 mg of microcrystalline cellulose; And
    [201] 4 mg of silicon dioxide (particle size between 2.4 and 3.6 μm).
    [202] Mixing was carried out for 6 minutes in a solidly mixer. The powder mixture was compressed into tablets weighing 320 mg.
    [203] Composition 3 (Tablet Code SS)
    [204] 105 mg of cartilage extract (prepared by enzymatic proteolytic hydrolysis of cartilage, filtration of hydrolysates and spray drying);
    [205] 100 mg of plant extract (about 1.5 mg of lycopene extracted from tomato and about 14 mg of flavonoids extracted from grape seeds, the residue being soy fiber, tomato oil and silicon dioxide; Alextan® from Milan Indenda, Italy) ;
    [206] Inulin 62 mg;
    [207] 30 mg of ascorbic acid;
    [208] 15 mg of zinc gluconate; And
    [209] 13 mg of silicon dioxide (particle size between 2.4 and 3.6 μm).
    [210] Mixing was carried out for 6 minutes in a solidly mixer. The powder mixture was compressed into tablets weighing 325 mg.
    [211] Conventional Compositions
    [212] FE: 105 mg
    [213] GE: 13.75 mg
    [214] TE: 14.38 mg (this lycopene has 10% = 1.44 mg)
    [215] Example 5
    [216] The composition of Example 1 was tested to determine the cognitive change of the consumer in the skin.
    [217] 129 volunteers were put into the study for 3 months and tablets containing the composition of Example 1 were taken daily. Before starting the test, the skin appearance and characteristics of these volunteers were recorded. After taking the composition of Example 1 for 1 month, 2 months and 3 months, the skin appearance and properties were evaluated. The evaluation criteria are as follows: 0-no change of state, 1-slightly improved, 2-improved, 3-significantly improved.
    [218] Fig. 4 shows the results of evaluation of the characteristics of "total skin condition", "flexibility", "skin around eyes" and "skin around mouth". % Improvement was expressed as the percentage of applicants who experienced improvement.
    [219] references
    [220]
    权利要求:
    Claims (49)
    [1" claim-type="Currently amended] Oral administration composition comprising a plant extract and cartilage extract, wherein the plant extract comprises grape seed extract and tomato extract.
    [2" claim-type="Currently amended] The composition of claim 2, wherein the plant extract comprises grape seed extract and tomato extract in a weight / weight ratio of about 2: 1 to 1: 2, preferably 1: 1.
    [3" claim-type="Currently amended] And a plant extract and a cartilage extract, wherein the plant extract comprises grape seed extract and lycopene at a weight / weight ratio of about 5: 1 to 15: 1, preferably about 10: 1.
    [4" claim-type="Currently amended] The composition of claim 1, wherein the cartilage extract and the plant extract are present in a weight / weight ratio of about 1: 2 to 2: 1, preferably about 1: 1.
    [5" claim-type="Currently amended] 5. The cartilage extract of claim 1, wherein the cartilage extract is each chondroitin ester, keratan ester, hyaluronic acid or an ester thereof, dermatan ester, heparin, heparan ester, each of which may optionally be linked to a peptide. And glycosaminoglycans selected from the group consisting of epimers and polymers thereof.
    [6" claim-type="Currently amended] The composition of claim 5, wherein the glycosaminoglycans are selected from the group consisting of chondroitin-4-sulfate, chondroitin-6-sulfate, and keratan sulfate, each of which can be linked to a peptide.
    [7" claim-type="Currently amended] The composition of claim 1, wherein the cartilage extract comprises chondroitin sulfate optionally bound to a peptide.
    [8" claim-type="Currently amended] The composition of claim 1 comprising less than 1% w / w collagen, preferably less than 0.5% w / w collagen, particularly preferably less than 0.1% w / w collagen. And most preferably does not contain collagen.
    [9" claim-type="Currently amended] 9 to 10% w / w lycopene, preferably 0.2 to 4% w / w lycopene, such as 0.3 to 2% w / w lycopene, most preferably 0.3 to 1% w / w lycopene, in particular 0.3 to 0.8% w / w, such as 0.3 to 0.6% lycopene.
    [10" claim-type="Currently amended] 10. The composition of claim 1, wherein the composition increases collagen synthesis by at least 35% as measured by Test Method A. 11.
    [11" claim-type="Currently amended] The composition according to any one of claims 1 to 9, wherein the composition has a deleterious effect of at least 40%, as measured by MMP-1 activity when compared to the control under the conditions of Test Method B. For example at least 45%, such as at least 50%.
    [12" claim-type="Currently amended] 10. The composition of any one of claims 1-9, wherein the composition has a formation of higher glycosylation end product (AGE) of at least 10%, such as at least 20%, as measured in comparison to the control under the conditions of Test Method C. For example at least 30%, 40%, 50% or 60%, preferably at least 70%, in particular at least 80% or 90%, most preferably at least 100% or 110%.
    [13" claim-type="Currently amended] The composition is
    i) cartilage, at least one compound extractable therefrom or a derivative thereof;
    ii) at least one hydrophilic antioxidant; And
    iii) at least one lipophilic antioxidant
    Wherein the composition increases collagen synthesis by at least 35% as measured by Test Method A.
    [14" claim-type="Currently amended] The composition of claim 13, wherein the at least one hydrophilic antioxidant is derived from grape seed extract.
    [15" claim-type="Currently amended] The composition of claim 13, wherein the at least one hydrophilic antioxidant is from a tomato extract.
    [16" claim-type="Currently amended] The composition of claim 13, wherein the one or more hydrophilic antioxidants are from natural or synthetic sources.
    [17" claim-type="Currently amended] The method of claim 16, wherein the natural source is pine bark, Vitis vinifera , Camelia sinensis , Aesculus hippocastanum , Gingo biloba , Cardus marianum , Vaccinium myrtillus , Silybum marianum The composition is selected from the group consisting of.
    [18" claim-type="Currently amended] The composition of claim 13, wherein the at least one hydrophilic antioxidant is oligomer polycyanidol.
    [19" claim-type="Currently amended] 19. The composition of any one of claims 13-18, wherein said at least one hydrophilic antioxidant is extractable from grape seeds of Vitis viifera.
    [20" claim-type="Currently amended] The composition of claim 13, wherein the one or more lipophilic antioxidants are from natural or synthetic sources.
    [21" claim-type="Currently amended] The composition of claim 20, wherein said natural source is tomato variety.
    [22" claim-type="Currently amended] The composition of claim 20, wherein the tomato extract is the sole source of lipophilic antioxidant.
    [23" claim-type="Currently amended] The composition of claim 21, wherein the tomato variety is Lycopersicum aesculentum .
    [24" claim-type="Currently amended] The method according to any one of claims 13 to 23, wherein the lipophilic antioxidant is α-carotene, β-carotene, γ-carotene, δ-carotene, lycopene (ψ, ψ-carotene), zeaxanthin, creep A composition comprising a carotenoid selected from the group consisting of toxanthine, lutein and xanthophyll.
    [25" claim-type="Currently amended] The composition of claim 13, wherein one of the one or more lipophilic oxidants is lycopene.
    [26" claim-type="Currently amended] 26. The method of claim 13, wherein 0.1 to 5% w / w of lycopene, preferably 0.2 to 4% w / w lycopene, such as 0.3 to 2% w / w lycopene, most preferably 0.3 to 1% w / w lycopene, in particular 0.3 to 0.8% w / w, such as 0.3 to 0.6% w / w lycopene.
    [27" claim-type="Currently amended] The method of claim 20, wherein the natural source of the at least one lipophilic antioxidant is approximately
    Lycopene 5-12%
    Tocopherol 1-1.5%
    Beta-carotene 0.05 to 0.15%
    Phytophene 0.5 to 0.75%
    Phytofluene 0.5 to 0.55%
    Composition comprising a.
    [28" claim-type="Currently amended] A composition according to claim 1, comprising less than 0.025% beta-carotene, preferably less than 0.02% beta-carotene, in particular less than 0.01% beta-carotene.
    [29" claim-type="Currently amended] The method of claim 13, wherein the increase in collagen synthesis is at least 40%, at least 45%, such as at least 50%, at least 55%, preferably at least 60%, such as at least 65%, 70%. Or more, most preferably at least 75% or at least 80%.
    [30" claim-type="Currently amended] 30. The composition of any one of claims 13-29, wherein the composition measures at least 40% of the deleterious effects of oxygen free radicals, as measured by MMP-1 activity when compared to the control under the conditions of Test Method B. For example at least 45%, such as at least 50%.
    [31" claim-type="Currently amended] 31. The composition of claim 30, wherein said deleterious effect is due to UV exposure.
    [32" claim-type="Currently amended] 32. The composition of any one of claims 13-31, wherein the composition has a formation of higher glycosylation end product (AGE) of at least 10%, such as at least 20%, as measured in comparison to the control under the conditions of Test Method C. For example at least 30%, 40%, 50% or 60%, preferably at least 70%, in particular at least 80% or 90%, most preferably at least 100% or 110%.
    [33" claim-type="Currently amended] 33. The method according to any of claims 13 to 32, wherein the hydrophilic antioxidant and the lipophilic antioxidant are from about 1: 1 to about 200: 1, such as 2: 1 to 100: 1, especially 5: 1 to 50. : 1, even more particularly 5: 1 to 20: 1, preferably 5: 1 to 15: 1, most preferably present at a weight / weight ratio in the range of about 7: 1 to 12: 1, such as 10: 1 Composition.
    [34" claim-type="Currently amended] 34. The method of any one of claims 13-33, wherein the cartilage, at least one compound extractable therefrom and the hydrophilic antioxidant are about 1: 1 to about 200: 1, such as 2: 1 to 100: 1, In particular in the range of 5: 1 to 50: 1, even more particularly 5: 1 to 20: 1, preferably 5: 1 to 15: 1, most preferably about 7: 1 to 12: 1, such as 10: 1. Composition present in weight / weight ratio.
    [35" claim-type="Currently amended] 35. The method of claim 13, wherein 0.25 to 15 mg of lycopene and 2.5 to 100 mg of grape seed extract, preferably 0.5 to 5 mg of lycopene and 5 to 50 mg of grape seed extract, in particular 0.75 to A composition comprising 2.5 mg lycopene and 10 to 30 mg grape seed extract, in particular 1 to 2.5 mg lycopene and 10 to 25 mg grape seed extract.
    [36" claim-type="Currently amended] 36. The composition of any one of claims 13-35, comprising 1-2.5 mg of lycopene, 5-50 mg of grape seed extract and 50-200 mg of cartilage extract.
    [37" claim-type="Currently amended] The method according to any one of claims 1 to 36,
    20 to 40% w / w cartilage extract, such as 25 to 35% w / w, preferably 27 to 35% w / w, such as 30 to 35% w / w cartilage extract;
    1 to 10% w / w grape seed extract, such as 2 to 8% w / w, preferably 3 to 7% w / w, such as 3 to 5% w / w grape seed extract; And
    1 to 10% w / w tomato extract, such as 2 to 8% w / w, preferably 3 to 7% w / w, such as 3 to 5% w / w tomato extract
    Composition comprising a.
    [38" claim-type="Currently amended] 38. The composition of any one of the preceding claims, further comprising an Acerola extract.
    [39" claim-type="Currently amended] The method according to any one of claims 1 to 38,
    Fish extract 100-110 mg;
    Plant extracts 95-105 mg;
    Acerola extract 25 to 35.00 mg;
    60 to 90 mg of microcrystalline cellulose; And
    Silicon dioxide 3.5 to 4.5 mg
    Wherein the plant extract comprises oligomer procyanidol and lycopene, wherein the fish extract comprises glycosaminoglycans.
    [40" claim-type="Currently amended] The method according to any one of claims 1 to 38,
    Fish extract 100-110 mg;
    Plant extracts 95-105 mg;
    Inulin 60-65 mg;
    Ascorbic acid 25 to 35.00 mg;
    Zinc gluconate 10-20 mg; And
    10 to 15 mg of silicon dioxide
    Wherein the plant extract comprises oligomer procyanidol and lycopene, wherein the fish extract comprises glycosaminoglycans.
    [41" claim-type="Currently amended] 41. The composition of any one of the preceding claims, wherein the grape seed extract is formulated in sustained release and the lycopene is formulated in a normal release form.
    [42" claim-type="Currently amended] 42. The composition according to any one of claims 1 to 41 for use as an oral beauty product, food or food supplement, medicament or diet.
    [43" claim-type="Currently amended] 43. The composition according to any one of claims 1 to 42, which is suitable for the general maintenance of healthy skin, the delay of the onset of skin degeneration due to aging or UV exposure and the treatment of signs of skin aging.
    [44" claim-type="Currently amended] The method of claim 1, wherein the skin is exposed to aging skin, sunlight or other forms of UV radiation, dry skin, rough skin, discolored skin, acne-prone skin, scarred skin, stretch marks ( stretch mark), for use in treating skin with eczema and psoriasis.
    [45" claim-type="Currently amended] 45. The composition according to any one of claims 1 to 44, wherein the composition is in the form of a solid formulation such as tablets, powders, granules, granules, capsules, flavors or liquids such as solutions, suspensions, tonics or syrups. The composition is administered in the form of a formulation.
    [46" claim-type="Currently amended] 42. Skin exposed to aging skin, sun or other forms of UV radiation, dry skin, rough skin, discolored skin, skin with acne, comprising oral administration of a composition according to any one of claims 1 to 41, Cosmetic or prophylactic treatment of skin with scars, stretch marks, eczema and psoriasis.
    [47" claim-type="Currently amended] 42. A method of cosmetic or prophylactic treatment of skin against signs of skin aging, damage resulting from exposure to UV radiation, comprising oral administration of a composition according to any one of claims 1 to 41.
    [48" claim-type="Currently amended] 42. A method of increasing collagen synthesis or reducing a decrease in collagen synthesis in the dermis comprising oral administration of a composition according to any one of claims 1 to 41.
    [49" claim-type="Currently amended] Prevention or delay of signs of skin aging, prevention or reduction of the harmful effects of UV radiation exposure, treatment of stretch marks, treatment of acne, relief of eczema symptoms, assistance in the formation of scars, reduction of scars, relief of psoriasis symptoms or rough skin, discolored skin Or the use of a composition according to any one of claims 1 to 41 in the manufacture of a medicament for the treatment of dry skin.
    类似技术:
    公开号 | 公开日 | 专利标题
    US20180256627A1|2018-09-13|Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and methods of use thereof
    AU2012287067B2|2016-12-08|Botanical antioxidant compositions and methods of preparation and use thereof
    CA2215210C|2002-06-25|Polyphenol fractions of tea, the use thereof and formulations containing them
    US6124268A|2000-09-26|Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof
    CA2123739C|2004-01-27|Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
    US6602526B2|2003-08-05|Oral compositions containing lotus
    US6468564B1|2002-10-22|Topical compositions containing lotus for skin treatment
    CA2657703C|2015-11-24|Use of a rice protein hydrolysate as pigmenting active principle
    US6756045B1|2004-06-29|Topically applied idebenone-containing agent with protective and regenerative effect
    RU2442564C2|2012-02-20|EXTRACTS OF Aphanizomenon Flos Aquae AND NUTRITIOUS, COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING BAESD ON THEM
    US5840681A|1998-11-24|X-ray induced skin damage protective composition
    TWI232103B|2005-05-11|Stable carotene-xanthophyll beadlet compositions and methods of use
    US7892523B2|2011-02-22|Cosmetic process for the treatment of the skin with sun-protection products and sun-protection products combination
    JP4100911B2|2008-06-11|Glutamate decarboxylase activator
    JP2005535617A|2005-11-24|Use of taurine to treat alopecia
    CN1222297C|2005-10-12|Combined cartilage and plant extract composition
    US5648377A|1997-07-15|Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
    KR20050114677A|2005-12-06|Composition for promoting production of type i collagen and/or elastin
    US20030104080A1|2003-06-05|Topical urea composition
    US5801192A|1998-09-01|Use of vitamin C or derivatives or analogues thereof promoting skin elastin synthesis
    US8022038B2|2011-09-20|Composition for acceleration of type I collagen production
    JP4685375B2|2011-05-18|Topical skin preparation
    US7090872B2|2006-08-15|Antioxidant, skin preparation for external use, cosmetic and food
    EP1390008B1|2008-07-09|Pharmaceutical and cosmetic compositions comprising phospholipid complexes of vitis vinifera and of centella asiactica
    US6488923B2|2002-12-03|Use of a flavonoid extract of Ginkgo biloba substantially devoid of terpenes, in the dentibuccal field, and composition containing such extract
    同族专利:
    公开号 | 公开日
    JP2003532680A|2003-11-05|
    RU2002133461A|2004-03-27|
    WO2001085182A2|2001-11-15|
    DE60117971T2|2006-10-12|
    IL152730D0|2003-06-24|
    EE05173B1|2009-06-15|
    AU2001258237B8|2006-02-09|
    HK1050629A1|2006-08-18|
    EP1283713B1|2006-03-15|
    ES2260220T3|2006-11-01|
    RU2271213C2|2006-03-10|
    AU5823701A|2001-11-20|
    CA2408544A1|2001-11-15|
    KR100917701B1|2009-09-21|
    CN1437475A|2003-08-20|
    EE200200635A|2004-04-15|
    MY136064A|2008-08-29|
    DK1283713T3|2006-07-10|
    DE60117971D1|2006-05-11|
    CZ20023970A3|2003-06-18|
    PL204004B1|2009-12-31|
    HU0301941A2|2003-09-29|
    EP1283713A2|2003-02-19|
    ZA200209682B|2004-03-01|
    US7435432B2|2008-10-14|
    AT320262T|2006-04-15|
    NZ523050A|2004-11-26|
    NO20025381L|2003-01-10|
    AU2001258237B2|2005-12-22|
    NO20025381D0|2002-11-11|
    CN1222297C|2005-10-12|
    MXPA02011133A|2004-08-19|
    PT1283713E|2006-08-31|
    WO2001085182A3|2002-03-28|
    AR028452A1|2003-05-07|
    US20020012714A1|2002-01-31|
    KR20080026663A|2008-03-25|
    IL152730A|2009-05-04|
    JP2008273963A|2008-11-13|
    PL364466A1|2004-12-13|
    BR0110940A|2003-07-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2000-05-12|Priority to DKPA200000782
    2000-05-12|Priority to DKPA200000782
    2001-05-10|Application filed by 벵트 크리스터 올손
    2001-05-10|Priority to PCT/DK2001/000331
    2003-02-26|Publication of KR20030016259A
    2009-09-21|Application granted
    2009-09-21|Publication of KR100917701B1
    优先权:
    申请号 | 申请日 | 专利标题
    DKPA200000782|2000-05-12|
    DKPA200000782|2000-05-12|
    PCT/DK2001/000331|WO2001085182A2|2000-05-12|2001-05-10|Combined cartilage and plant extract compositions|
    [返回顶部]